Pyrido[1,2-a]benzimidazole-Based Agents Active Against Tuberculosis (TB), Multidrug-Resistant (MDR) TB and Extensively Drug-Resistant (XDR) TB

Multi-Drug/Extensively Drug Resistant Tuberculosis (Mdr/Xdr-Tb): Renewed Global Battle Against Tuberculosis?

Multidrug resistant TB and extensively drug resistant TB

Resistance to anti-TB drugs is not an emerging phenomenon, but a process closely related to the implementation of chemotherapy against TB. Clinical evidence to prove the development of resistance to anti-TB drugs was provided by the Medical Research Council team in 1948, shortly after using streptomycin in (as?) monotherapy for TB treatments 1. As isoniazid, PAS and streptomycin were first used...

Prevalence of Pre-Extensively Drug-Resistant Tuberculosis (Pre XDR-TB) and Extensively Drug-Resistant Tuberculosis (XDR-TB) among Pulmonary Multidrug Resistant Tuberculosis (MDR-TB) at a Tertiary Care Center in Mumbai

Background: India is a high burden country for Tuberculosis (TB). As per the World Health Organization (WHO) statistics, 24000 cases of Multi Drug Resistant (MDR) TB were diagnosed in India in 2014. MDR-TB patients consist of a heterogeneous cohort and management has its challenges. Aims and objectives: We studied the prevalence of PreExtensively Drug Resistant TB (Pre XDR-TB) and Extensively D...

Extensively drug resistant tuberculosis (XDR-TB): A potential threat

Emergence of extensively drug resistant tuberculosis (XDR-TB) has been reported by more than 55 countries. XDR-TB is considered as untreatable and highly fatal disease. In developing countries like India, number of cases of multi-drug resistant tuberculosis (MDR-TB) and XDR-TB are increasing. Emergence of resistance to Isoniazid and Rifampicin, the two most effective and well tolerated agents, ...

Epidemiology of Multidrug Resistant Tuberculosis (MDR-TB)

The history of tuberculosis treatment has observed sequential development of resistance to anti-tuberculosis drugs over the decades. Para amino salicylic acid (PAS) and isoniazid (INH) were introduced to reduce the development of streptomycin (SM) resistance, which heralded the era of combination treatment for tuberculosis [1]. Within 20 years, resistance to both INH and SM was already a challe...